{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T12:07:59.028769+00:00","company":{"ticker":"JBIO","cik":1798749,"company_name":"Jade Biosciences, Inc."},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"24a8816e63ea26fdb74c6ee23f76f3b7a26a228e","cik":1798749,"ticker":"JBIO","company_name":"Jade Biosciences, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss totaled $40.4 million for the first quarter ended March 31, 2026","period_text":"the quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":null},"claim":"Jade Biosciences, Inc. reported the quarter ended March 31, 2026 results: net income Net loss totaled $40.4 million for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 7, 2026, Jade Biosciences, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-211973","anchor_url":"https://secwatch.observer/filing/0001193125-26-211973#claim-24a8816e63ea26fdb74c6ee23f76f3b7a26a228e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526211973/0001193125-26-211973-index.htm"},{"fact_type":"executive_change","fact_key":"5817d2fed5","cik":1798749,"ticker":"JBIO","company_name":"Jade Biosciences, Inc.","filed_at":"2024-10-10T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-10-06","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Maha Katabi resigned as Director at Jade Biosciences, Inc..","evidence_excerpt":"On October 6, 2024, Maha Katabi, Ph.D., provided notice of her resignation from the board of directors (the “Board”) of Aerovate Therapeutics, Inc. (the “Company”), effective as of October 6, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001798749-24-000052","anchor_url":"https://secwatch.observer/filing/0001798749-24-000052#claim-5817d2fed5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1798749/000179874924000052/0001798749-24-000052-index.htm"},{"fact_type":"earnings_release","fact_key":"9b171013b7a300d0934a0efc95f485003c81fbff","cik":1798749,"ticker":"JBIO","company_name":"Jade Biosciences, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the quarter ended March 31, 2024 was $23.2 million as compared to $16.5 million for the quarter ended March","period_text":"quarter ended March 31, 2024","report_date":"2024-05-13","result_type":"reported_results","revenue_text":null},"claim":"Jade Biosciences, Inc. reported quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024 was $23.2 million as compared to $16.5 million for the quarter ended March.","evidence_excerpt":"Net loss for the quarter ended March 31, 2024 was $23.2 million as compared to $16.5 million for the quarter ended March 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001798749-24-000029","anchor_url":"https://secwatch.observer/filing/0001798749-24-000029#claim-9b171013b7a300d0934a0efc95f485003c81fbff","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1798749/000179874924000029/0001798749-24-000029-index.htm"},{"fact_type":"earnings_release","fact_key":"412d3fd74a7b783abae3b15b2e4bffa12d8056f9","cik":1798749,"ticker":"JBIO","company_name":"Jade Biosciences, Inc.","filed_at":"2024-03-25T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$75.5 million","period_text":"the year ended December 31, 2023","report_date":"2024-03-25","result_type":"reported_results","revenue_text":null},"claim":"Jade Biosciences, Inc. reported the year ended December 31, 2023 results: net income $75.5 million.","evidence_excerpt":"Net loss for the year ended December 31, 2023 was $75.5 million as compared to $51.5 million for the year ended December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001798749-24-000014","anchor_url":"https://secwatch.observer/filing/0001798749-24-000014#claim-412d3fd74a7b783abae3b15b2e4bffa12d8056f9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1798749/000179874924000014/0001798749-24-000014-index.htm"}]}